Green Park & Golf Ventures
Venture capitalDallas · Seed–Growth · 10 people tracked
Investment thesis
Green Park & Golf seeks investment opportunities offering above-market returns in medical-related companies. The firm targets companies with fresh, disruptive ideas in healthcare, large market opportunities with high barriers to entry, and passionate, seasoned management teams. The investment strategy is grounded in the successful track record of the founding partners in building MedicalEdge and PhyServe, emphasizing compassionate company cultures, aligned incentives across stakeholders, and leveraging the firm's superior deal flow from its extensive operational and investment network.
Source: firm website, verified Jul 21, 2026.
Team · 10 people
from the firm's websiteA founding partner of Green Park & Golf Ventures, Soderstrom brings extensive board experience and operational expertise to early-stage healthcare investment.
Founding partner of Green Park & Golf Ventures and emergency medicine physician with 13 years of clinical practice. Founded Medical Edge Healthcare Group and co-founded Metroplex Emergency Physicians Associates and Physician Support Resources; is also a founder of Caddis Partners and Health Wildcatters accelerator.
A founding member of Green Park & Golf Ventures with medical training from Southwestern Medical School. Dr. Heighten co-founded MedicalEdge and PhyServe before establishing the fund.
A seasoned investor with executive experience serving as Investment Partner with GPG Ventures' Austin office, focused on national healthcare venture investment.
Managing Partner of GPG Ventures – Houston with a track record as an active venture investor in early-stage medical device and biotech companies.
Joined GPG Ventures – Houston in May 2019 as Principal overseeing deal pipeline management and evaluation of potential investments.
Joined Green Park & Golf in 2017 as an Analyst with a background in Neuroscience from graduate studies.
Joined Green Park & Golf Ventures in 2025 as Head of Investor Relations, managing investor communications and stakeholder interactions.
The first employee of Green Park & Golf Ventures, Garcia has been instrumental in the firm's evolution and deal sourcing since inception.
Chief Scientific Officer at Green Park & Golf Ventures since 2017 with a Ph.D. in Neuroscience from UT Southwestern Medical Center. Leads diligence efforts across the firm's healthcare and technology portfolio with published research expertise in molecular biology and cellular mechanisms.
What they invest in
from 11 of 56 portfolio companiesBiotech ×5AI & Machine Learning ×4Healthtech ×4Medical Devices ×4Enterprise Software ×3Data & Infrastructure ×2Deep Tech ×2Digital Health ×2
HQs:United States×1
Investments · 56 tracked
founders shown can be your intro pathCariloop provides digital and human-centered support services to relieve stress and anxiety experienced by family caregivers. The platform serves individuals managing the care of aging parents, children, and other loved ones.
Enterprise SoftwareHealthtechHR TechImpact & Social GoodSaaS
Michael Walsh(Co-Founder, Chief Executive Officer, and Board Chair)
Hypergiant develops AI-enabled software platforms that process data and deliver actionable intelligence for rapid decision-making, serving Fortune 500 companies and government agencies. The platform provides visualization and analysis capabilities across strategic and tactical levels for mission-critical operations.
AI & Machine LearningData & InfrastructureDefense TechEnterprise SoftwareAustin, US
Ben Lamm
Iterion Therapeutics is a clinical-stage biopharmaceutical company developing Tegavivint, a targeted Wnt/β-catenin inhibitor for cancers with Wnt-driven mutations, primarily hepatocellular carcinoma and colorectal cancer. The drug works by blocking β-catenin's oncogenic activity through TBL1 inhibition while minimizing the toxicities associated with upstream Wnt inhibitors.
BiotechMedical Devices
Lantern Pharma develops AI and machine learning tools to identify which patients will respond to oncology drugs before clinical trials, reducing development costs and improving approval odds. The platform serves pharmaceutical companies developing cancer therapies.
AI & Machine LearningBiotech
Mission Bio develops single-cell biology tools and platforms for researchers and clinicians to enable precision medicine discovery and cancer treatment. The company serves the biomedical research and clinical diagnostics market.
BiotechDeep TechDigital HealthMedical Devices
Proscia provides a digital pathology software platform that converts glass microscope slides into high-resolution digital images for viewing, management, and analysis by pathologists and research teams. The platform enables clinical laboratories and life sciences organizations to improve workflow efficiency, support remote collaboration, and integrate artificial intelligence tools for quantitative tissue analysis and biomarker detection.
AI & Machine LearningBiotechHealthtechMedical Devices<UNKNOWN>
Savara is a biopharmaceutical company developing treatments for autoimmune pulmonary alveolar proteinosis (autoimmune PAP) and other rare lung diseases. The company focuses on novel therapeutic approaches for patients with rare respiratory conditions.
BiotechHealthtechMedical Devices
Matt Pauls(Chair of the Board of Directors and Chief Executive Officer)
Supergoop makes a line of SPF sunscreen products designed for different skin tones, activities, and occasions. The brand serves consumers seeking sun protection products.
ConsumerWellness & Fitness
Validic operates a health IoT platform that connects over 700 medical devices and health apps to health systems, health plans, and life sciences organizations for clinical use. The company integrates siloed personal health data into actionable clinical workflows.
Data & InfrastructureDigital HealthHealthtechIoT
Worlds develops AI technology for processing and analyzing visual data in spatial and temporal context to enable enterprise applications in the physical world.
Advanced ManufacturingAI & Machine LearningDeep TechEnterprise Software
Dave Copps(CEO)Chris Rhode(President)
Frequently asked questions
- What stage does Green Park & Golf Ventures invest at?
- Green Park & Golf Ventures invests at the Seed, Series A, Series B, Growth stages.
- What is Green Park & Golf Ventures's typical check size?
- Green Park & Golf Ventures typically writes checks of $500K – $2M.
- What sectors does Green Park & Golf Ventures focus on?
- Green Park & Golf Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Green Park & Golf Ventures located?
- Green Park & Golf Ventures is headquartered in Dallas, US.
Similar investors
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
Breyer Capital is a venture capital firm that invests in high-impact entrepreneurs with a strategic focus on companies leveraging artificial intelligence and machine learning to transform technology sectors globally.
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
GV is Alphabet's venture capital arm, established in 2009 as Google Ventures. Operating with long time horizons and over $13 billion in assets under management, the firm invests across technology and life sciences sectors from seed to growth stages, supporting 400 active portfolio companies across North America, Europe, and Israel.
Innovestor is a Finnish investment manager that operates across venture capital, real estate, and energy storage sectors. The firm invests in early-stage technology and life science startups, energy-efficient commercial real estate, and battery storage and solar solutions. Innovestor also provides corporate venturing advisory services.